Apyx Medical Q2 2026 Earnings Report

Apyx Medical EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.06
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Apyx Medical Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $13.18 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Apyx Medical Announcement Details

• Quarter: Q2 2026
• Date: 8/6/2026
• Time: Before Market Opens
• Conference Call Date: Thursday, August 6, 2026
• Conference Call Time: 4:30PM ET

Apyx Medical (NASDAQ:APYX) (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions. Its surgical devices are designed to enhance hemostasis, dissection and ablation in minimally invasive and open procedures, while its Renuvion system has gained adoption in cosmetic surgery for skin contraction and soft-tissue coagulation. The company supports its products with a combination of clinical training programs, customer service and collaborative research initiatives aimed at demonstrating safety and efficacy in various treatment settings.

Established in early 2021 through a strategic combination of assets acquired from Bovie Medical, Apyx Medical has pursued a growth strategy centered on innovation and targeted commercial expansion. The company operates its headquarters in Clearwater, Florida, and maintains manufacturing and distribution capabilities to support an expanding global footprint. Guided by a leadership team with experience in medical technology and regulatory affairs, Apyx Medical continues to invest in product development and clinical evidence to broaden its treatment applications and enhance patient outcomes.